Eberconazole Nitrate

Background Fungal infections are one of the most common dermatological issues worldwide. Candida species-caused fungal infections are frequent on the cutaneous surface. Eberconazole (EBZ) has the strongest antifungal action against Candida spp., the major source of fungal infections.Method In the present study, the cold method followed by probe sonication was used to create EBZ-loaded ethosomal dispersion. The solubility of ethosomes in different lipids and surfactants was used to choose these components. Under magnetic stirring, the dispersion was absorbed into a carbopol 934 gel. In vitro antifungal activity was performed using the Agar well diffusion method, and their topical effectiveness against pathogenic Candida albicans was compared to that of a marketed formulation containing EBZ.Results Eberconazol incorporated into gel displayed sustained release in an in vitro release assay. Based on the zone of inhibition diameters, EBZ formulation was determined to be efficient against C. albicans when compared to the commercialized cream and plain gel.Conclusion Based on these findings, the current study found that EBZ possesses significant antifungal efficacy against C. albicans.

Topical antifungals especially azole group of drugs are effective agents in the treatment of dermatophytoses producing 100% clinical and mycological cure. Each of them vary having specific characteristics to tackle several clinical challenges like high relapse rate, recurrences and quality of life.

To compare the efficacy and safety of Eberconazole and Sertaconazole in tinea infection.

This was a randomized, observer-blinded, parallel-group study conducted at a dermatology out-patient department (OPD) of tertiary care teaching hospital in Puducherry. 85 patients with tinea corporis and tinea cruris infections who visited the dermatology OPD were enrolled in this study. The treatment phase involved two groups receiving either Sertaconazole 2% cream or Eberconazole 1% applied topically twice daily for 4 weeks. At the end of treatment phase, there was a 'follow-up phase' at the end of 4 weeks, where the patients were assessed clinically and mycologically. The data were analyzed using descriptive statistics using MS Excel version 2019 and SPSS version 15 for Windows.

The primary efficacy variables namely change in pruritus, erythema, induration, scaling and mycological cure significantly improved in both the groups, as compared to baseline (P < 0.001), in the treatment phase and follow-up phase. Intergroup comparison with respect to pruritus and scaling showed significant difference (P < 0.001), suggestive of better reduction of pruritus and scaling scores at 4 weeks with Sertaconazole when compared to Eberconazole.

Sertaconazole was better than Eberconazole in relieving signs and symptoms of dermatophytoses, especially pruritus, thereby improving patients' quality of life.